| 35.74 Data as of May 17 |  +0.02 / +0.06%Today’s Change | 28.62 Today|||52-Week Range 37.78 | +14.40% Year-to-Date |
| Synta Is a Run-Up Trade Into ASCO Lung Cancer Data May 14 / TheStreet.com | Hospira Becomes #24 Most Shorted S&P 500 Component, Replacing Leggett & Platt May 10 / TheStreet.com |
| Hospira Inc. (HSP): Today's Featured Health Care Laggard May 13 / TheStreet.com |
| Previous close | 35.72 |
| Today’s open | 35.96 |
| Day’s range | 35.45 - 36.20 |
| Volume | 1,300,878 |
| Average volume (3 months) | 1,645,895 |
| Market cap | $5.9B |
| Dividend yield | -- |
| Earnings growth (last year) | -- |
| Earnings growth (this year) | +1.02% |
| Earnings growth (next 5 years) | +4.74% |
| Revenue growth (last year) | +0.86% |
| P/E ratio | NM |
| Price/Sales | 1.26 |
| Price/Book | 1.94 |
| Today’s change | Today’s % change | |
|---|---|---|
| ELNElan Corporation PLC | +0.08 | +0.69% |
| PCYCPharmacyclics Inc | +0.97 | +1.16% |
| RDYDr.Reddy's Laborator... | -0.61 | -1.58% |
| ONXXOnyx Pharmaceuticals... | +0.30 | +0.31% |
| Next reporting date | July 31, 2013 |
| EPS forecast (this quarter) | $0.51 |
| Annual revenue (last year) | $4.1B |
| Annual profit (last year) | $44.2M |
| Net profit margin | 1.08% |
Sector Health Technology |
Industry Medical Specialties |
Chief Executive Officer & Director F. Michael Ball, MBA |
Senior Vice President- Operations John B. Elliot |
Corporate headquarters Lake Forest, Illinois |
.
